Overview

A Dose Ranging Placebo-controlled Double-blind Study to Evaluate the Safety, Pharmacokinetics and Efficacy of 610 in Participants With Severe Eosinophilic Asthma

Status:
Active, not recruiting

Trial end date:
2023-09-01

Target enrollment:

Participant gender:

Summary

This study will assess the safety, tolerability, pharmacokinetics and preliminary efficacy of 610 as an adjunctive therapy in adult subjects with severe eosinophilic asthma.

Phase:

Phase 1

Details

Lead Sponsor:

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.